Application

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

---

PTO- 1478

Approved for use through 10/31/2024. OMB 0651-0009

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Trademark/Service Mark Application, Principal Register

Serial Number: 97602539

Filing Date: 09/22/2022

To the Commissioner for Trademarks:

MARK: FLUENCY (Standard Characters, see mark)
The literal element of the mark consists of FLUENCY. The mark consists of standard characters, without claim to any particular font style, size, or color.
The applicant, Immuneering Corporation, a corporation of Delaware, having an address of
      245 Main Street, Second Floor
      Cambridge, Massachusetts 02142
      United States
      XXXX

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 042:  drug discovery services provided through a computer software platform used for research and development in the field of drugs; pharmaceutical research and development; providing medical research and scientific information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; providing medical and scientific research information in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials via the internet; research and development of new products; medical and scientific research in the fields of pharmaceuticals, biology, chemistry, biochemistry, biotechnology, and clinical trials; platform as a service (PAAS) or software as a service (SAAS) featuring computer software platforms using biology and chemistry analytics for determining drug candidates with reduced toxicity; platform as a service (PAAS) or software as a service (SAAS) featuring computer software platforms for database mining, database analysis, database management and the application of artificial intelligence; consultancy in relation to the development and implementation of software and software based applications; drug discovery services using artificial intelligence to predict, identify, and rank drug candidates; artificial intelligence-assisted automated drug discovery services to predict, identify and rank the binding potential of chemical compounds to a target protein
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.



The owner's/holder's proposed attorney information: Ian W. Gillies. Other appointed attorneys are John B. Sganga, Jr., Edward A. Schlatter, Gerard von Hoffmann, Joseph R. Re, Catherine J. Holland, Jeffrey L. Van Hoosear, Daniel E. Altman, Stephen C. Jensen, Lynda J. Zadra Symes, Steven J. Nataupsky, Paul A. Stewart, Joseph F. Jennings, Craig S. Summers, Ronald J. Schoenbaum, John R. King, Adeel S. Akhtar, David N. Weiss, Douglas G. Muehlhauser, Lori Lee Yamato, Michael K. Friedland, Stacey R. Halpern, Jon W. Gurka, Joseph M. Reisman, Michael L. Fuller, Paul N. Conover, Robert J. Roby, Sabing H. Lee, Karoline A. Delaney, William R. Zimmerman, Eric S. Furman, Susan M. Natland, Rabinder N. Narula, Bruce S. Itchkawitz, John M. Grover, Irfan A. Lateef, Amy Christensen Chun, Mark J. Gallagher, Brian C. Horne, Payson LeMeilleur, Sheila N. Swaroop, Benjamin Katzenellenbogen, Andrew N. Merickel, Linda H. Liu, James F. Herkenhoff, Andrew M. Douglas, Salima A. Merani, Jonathan A. Hyman, Curtiss C. Dosier, Joseph J. Mallon, Sean M. Murray, Christy G. Lea, Perry D. Oldham, Russell M. Jeide, Zi Y. Wong, Matthew S. Bellinger, Gregory A. Hermanson, Lauren K. Katzenellenbogen, Ted M. Cannon, Carol Pitzel Cruz, Josue A. Villalta, Andrew I. Kimmel, Brenden Gingrich, Maria Culic Anderson, Melanie J. Seelig, Mauricio A. Uribe, Curtis R. Huffmire, Christopher L. Ross, Eli A. Loots, Ryan E. Melnick, Yanna S. Bouris, Philip M. Nelson, Marko R. Zoretic, Kerry S. Taylor, Derek C. Dailey, Jarom D. Kesler, Colin B. Heideman, Theodore G. Papagiannis, Nicholas M. Zovko, Adam J. Gilbert, Kimberly J. Miller, Thomas Y. Yee, Agnes Juang, Jason J. Jardine, Jared C. Bunker, Lance D. Smemoe, Joshua J. Stowell, Jonathan E. Bachand, Ali S. Razai, Terry K. Tullis, Derek R. Bayles, Cheryl T. Burgess, Gregory B. Phillips, Brian C. Claassen, Mark Lezama, Sean P. Ambrosius, Stephen W. Larson, John L. Paik, Michael R. Christensen, Benjamin J. Everton, Jason A. Gersting, Baraa Kahf, Alan G. Laquer, Vlad Teplitskiy, Jeffery L. Hallstrom, Maria Victoria Stout, William O. Adams, Ian W. Gillies, Andrew W. Lloyd, Mark D. Kachner, Lincoln S. Essig, David R. Trossen, Aaron M. Davis, Jason R. Swartz, Benjamin B. Anger, Jason A. Champion, Daniel V. Gibson, Jeremy J. Carney, Karen Cassidy Selvaggio, Adam B. Powell, Karen J. Lenker, Bryan G. McWhorter, Nathanael R. Luman, Andrea L. Cheek, Damien J. Howard, Jane Q. Dai, Shannon Lam, Peter Law, Mark Metzke, Jacob Peterson, Christie R.W. Matthaei, Vladimir S. Lozan, Paul S. Stellman, Heungsoo Choi, Nicole Rossi Townes, Vikas Bhargava, Jeremy A. Anapol, Scott A. Cromar, Kendall M. Loebbaka, David R. Schmidt, Harnik Shukla, Charlene A. Azema, Morgan R. Coates, Jessica L. Achtsam, Jonathan A. Menkes, Rosaleen H. Chou, Kyu S. Min, Chang Sik Lim, Thomas S.H. Cowan, Devanie A. DuFour, Hans L. Mayer, Jessica C. Sganga, Justin J. Gillett, Alexander J. Martinez, Brian M. Graham, Brian J. Flynn, Mitchell B. Hadley, Robert J. Hilton, Daniel P. Hughes, Andrew E. Morrell, Catherine R. Gourash, Jeremiah S. Helm, David M. Cohen, Jordan Gottdank, Nathan D. Reeves, Brandon G. Smith, Xiaoyan Sabrina Wang, Kregg A. Koch, Deborah S. Shepherd, Mark D. Marsden, Joan Y. Chan, Nicholas A. Belair, Angela K. Dremann, Michael Scott Forbes, Elenore Niu, Mark E. Davis, Daniel C. Kiang, Keith M. Lim, Ashley C. Morales, Jordan M. Cox, Albert J. Sueiras, Mark Rubinshtein, Clayton R. Henson, Daniel A. Kamkar, Jacob R. Rosenbaum, Douglas B. Wentzel, Aryeh N. Feinstein, Aaron S. Johnson, Bryan J. Johnson, Chanell Khosrowabadi, Lindsay A. Laddaran, Janet M. Allendorph, Alexander Zeng, Adam R. Aquino, Samuel I. Cockriel, Serah R. Friedman, Bita Kianian, Eric R. Malmgren, Justin E. Culbertson, Marissa M. Rosenbaum, Brok S. Humbert, Karl W. Kowallis, Christopher L. Lewis, Ben K. Shiroma, Makoto Tsunozaki, James Yang, Matthew S. Friedrichs, David G. Kim, Silas K. Alexander, Thomas S. Loy, Nima Zargari, Benjamin L. Black, Kenneth K. Wang, Brian C. Barnes, Emily J. Asgari, Spencer R. Carter, Xiaoyu Shelley Chen, Alexander P. Slafkosky, Laura E. Liebman, Katherine R. McMorrow, Alexander G. Trimes, Logan P. Young, Julie T. Vo, Matthew I. Burton, Robert C. Arbulu, Steven N. Friedland, Michelle J. Ziperstein, Cesar A. Estrada, Hyunjin Park, Julia N. Hanson, Brianne M. Kingery, Joshua C. Loader, Alistair J. McIntyre, Kenneth P. McNeill, Morgan E. Robertson, Clint A. Saylor, Joseph A.R. Gerber, Holly M. Gordon, Yusuke Hirai, Erin M. Cardinal, and Amit Kulkarni. Ian W. Gillies of Knobbe, Martens, Olson & Bear, LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      2040 Main Street, 14th Floor
      Irvine, California 92614
      United States
      efiling@knobbe.com
The docket/reference number is IMMU.001T.
Ian W. Gillies submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:

Ian W. Gillies

PRIMARY EMAIL FOR CORRESPONDENCE: efiling@knobbe.com       SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $350 has been submitted with the application, representing payment for 1 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce and was in use in commerce as of the filing date of the application on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application and was used on or in connection with the goods/services in the application as of the application filing date; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce and had a bona fide intention to use the mark in commerce as of the application filing date on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Ian W. Gillies/   Date: 09/22/2022
Signatory's Name: Ian W. Gillies
Signatory's Position: Attorney of Record, California Bar Member
Signatory's Phone Number: 858-707-4000
Signature method: Sent to third party for signature
Payment Sale Number: 97602539
Payment Accounting Date: 09/22/2022

Serial Number: 97602539
Internet Transmission Date: Thu Sep 22 14:15:45 ET 2022
TEAS Stamp: USPTO/BAS-XX.XX.XXX.XX-20220922141546677
570-97602539-820a02ffa12aa539fda8946d7af
c84dcf7d21d40abf32943ece9e5d9a1439b7e6-C
C-15450779-20220921121546831040